diazeniumdiolate has been researched along with Lung-Neoplasms* in 2 studies
2 other study(ies) available for diazeniumdiolate and Lung-Neoplasms
| Article | Year |
|---|---|
Novel α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive nitric oxide donors with anti-lung cancer activity.
A novel type of hydrogen peroxide (H2O2)-activated diazeniumdiolate based on an α-ketoamide moietey was developed as a nitric oxide (NO) donor. KA-NO-4 inhibited lung cancer cells with submicromolar activity. The H2O2-responsive behaviour of KA-NO-4 was thoroughly investigated. The NO-centered mechanism of action of KA-NO-4 was intracellularly studied. Topics: Amides; Antineoplastic Agents; Apoptosis; Azo Compounds; Cell Line, Tumor; Cell Movement; Humans; Hydrogen Peroxide; Lung Neoplasms; Nitric Oxide; Nitric Oxide Donors | 2019 |
Synthesis and chemical and biological comparison of nitroxyl- and nitric oxide-releasing diazeniumdiolate-based aspirin derivatives.
Structural modifications of nonsteroidal anti-inflammatory drugs (NSAIDs) have successfully reduced the side effect of gastrointestinal ulceration without affecting anti-inflammatory activity, but they may increase the risk of myocardial infarction with chronic use. The fact that nitroxyl (HNO) reduces platelet aggregation, preconditions against myocardial infarction, and enhances contractility led us to synthesize a diazeniumdiolate-based HNO-releasing aspirin and to compare it to an NO-releasing analogue. Here, the decomposition mechanisms are described for these compounds. In addition to protection against stomach ulceration, these prodrugs exhibited significantly enhanced cytotoxcity compared to either aspirin or the parent diazeniumdiolate toward nonsmall cell lung carcinoma cells (A549), but they were not appreciably toxic toward endothelial cells (HUVECs). The HNO-NSAID prodrug inhibited cylcooxgenase-2 and glyceraldehyde 3-phosphate dehydrogenase activity and triggered significant sarcomere shortening on murine ventricular myocytes compared to control. Together, these anti-inflammatory, antineoplasic, and contractile properties suggest the potential of HNO-NSAIDs in the treatment of inflammation, cancer, or heart failure. Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azo Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Enzyme Inhibitors; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Molecular Structure; Myocytes, Cardiac; Nitric Oxide; Nitrogen Oxides; Prodrugs; Sarcomeres | 2013 |